Clinical Trial News and Research

RSS

New research ties mushrooms to potential health outcomes

New research published as abstracts in The FASEB Journal and presented at Experimental Biology 2013 ties mushrooms to potential health outcomes - demonstrating that mushrooms provide more to a dish than just flavor.

24 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.

24 Apr 2013

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.

23 Apr 2013

AfriCoLeish receives grant from European Union to test new treatments for kala-azar

Research and development (R&D) project, AfriCoLeish, is supported by the European Union Seventh Framework Programme (EU FP7) through a grant of -3 million. The project will run for three years and aims to test new treatments for kala-azar (visceral leishmaniasis, or VL) and co-infection of the disease with HIV in Ethiopia and Sudan.

23 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

Study: Atrophy in an important area of brain predicts multiple sclerosis

Magnetic resonance imaging (MRI) measurements of atrophy in an important area of the brain are an accurate predictor of multiple sclerosis (MS), according to a new study published online in the journal Radiology.

23 Apr 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.

23 Apr 2013

White button mushrooms can help maintain weight loss, say researchers

New research published as an abstract in The FASEB Journal and presented at Experimental Biology 2013 (EB 2013) on Monday, April 22 ties mushrooms to positive health outcomes in the area of weight management.

23 Apr 2013

BAROnova presents ENDObesity I clinical trial data at SAGES meeting

BAROnova, Inc., recently presented data from their ENDObesity I clinical trial at the annual Society of American Gastrointestinal and Endoscopic Surgeons meeting.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

Researchers find innovative approach to treat lazy eye disorder

A research team led by Dr. Robert Hess from McGill University and the Research Institute of the McGill University Health Centre has used the popular puzzle video game Tetris in an innovative approach to treat adult amblyopia, commonly known as "lazy eye".

23 Apr 2013

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.

23 Apr 2013

Clinical Trial News and Research

New research ties mushrooms to potential health outcomes

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

Investigational treatment for ALS passes early phase clinical trial for safety

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

AfriCoLeish receives grant from European Union to test new treatments for kala-azar

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Study: Atrophy in an important area of brain predicts multiple sclerosis

Unavoidable damage to heart and lungs can be limited by using CVD drug

White button mushrooms can help maintain weight loss, say researchers

BAROnova presents ENDObesity I clinical trial data at SAGES meeting

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

Researchers find innovative approach to treat lazy eye disorder

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

Pergamum reaches LPLV in Phase I/II trial of LL-37 for treatment of hard-to-heal venous leg ulcers

Study: Image-guided brachytherapy prevents growth of cervical tumour in over 90% of patients

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer